Back to top
more

BeiGene (BGNE)

(Real Time Quote from BATS)

$205.66 USD

205.66
23,019

+2.93 (1.45%)

Updated Nov 7, 2024 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

BeiGene (BGNE) in Focus: Stock Moves 8.7% Higher

by Zacks Equity Research

BeiGene (BGNE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Amgen (AMGN) Invests Further in China-Based Oncology Partner

by Zacks Equity Research

Amgen (AMGN) announces additional investment of approximately $421 million in BeiGene. The companies have a collaboration for oncology products signed in 2019.

Leap Therapeutics Surges on License Agreement With BieGene

by Zacks Equity Research

Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.

BeiGene Gets Approval for Lymphoma Drug Tislelizumab in China

by Zacks Equity Research

BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.

The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Navient, BeiGene, SPS Commerce and Chipotle Mexican Grill

AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates

by Zacks Equity Research

AMAG disappoints investors with earnings and sales miss in the third quarter.

4 Stocks to Buy From Sectors With Maximum Job Gains

by Zacks Equity Research

The American jobs' market added new positions in October at a better-than-expected pace. Here's how to make the most of it.

Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance

by Zacks Equity Research

Repligen (RGEN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

BeiGene, Ltd. (BGNE) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does BeiGene, Ltd. (BGNE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Reata Successfully Completes Neuromuscular Disorder Study

by Zacks Equity Research

Reata (RETA) rallies following the successful completion of a pivotal study evaluating omaveloxolone as a potential treatment for Friedreich's ataxia, a progressive neuromuscular disorder.

BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA

by Zacks Equity Research

The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.

Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View

by Zacks Equity Research

Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.

Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates

by Zacks Equity Research

Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.

AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

by Zacks Equity Research

AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.

Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

by Zacks Equity Research

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.

PDL BioPharma (PDLI) Q2 Earnings Top Mark, Revenues Fall Y/Y

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings exceed estimates in the second quarter of 2019. However, the company generates negative revenues due to a change in the fair value of royalty rights.

Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies

by Zacks Equity Research

Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

Why Earnings Season Could Be Great for BeiGene (BGNE)

by Zacks Equity Research

BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.

Can Pharmacy Services Drive CVS Health's (CVS) Q2 Earnings?

by Zacks Equity Research

Akin to the previous quarters, net new business and the steady uptake of Maintenance Choice programs are likely to bolster CVS Health's (CVS) PBM business in Q2.

Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018

by Zacks Equity Research

Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.

Intrexon (XON) Reports Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Intrexon (XON) incurs narrower-than-expected loss in the fourth quarter of 2018.

Horizon Pharma's (HZNP) Stock Up on Q4 Earnings & Sales Beat

by Zacks Equity Research

Horizon Pharma's (HZNP) earnings and sales beat estimates in the fourth quarter of 2018.

BeiGene, Ltd. (BGNE) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

BeiGene, Ltd. (BGNE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BeiGene, Ltd. (BGNE) Is Up 12.82% in One Week: What You Should Know

by Zacks Equity Research

Does BeiGene, Ltd. (BGNE) have what it takes to be a top stock pick for momentum investors? Let's find out.